{"id":"tak-536","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-536 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"TAK-536 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:27.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05107960","phase":"","title":"A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Hypertension","enrollment":5},{"nctId":"NCT06990204","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)","status":"NOT_YET_RECRUITING","sponsor":"Gedeon Richter Plc.","startDate":"2025-06-06","conditions":"Hypertension","enrollment":56},{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":"Hypertension","enrollment":377},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT04668157","phase":"PHASE3","title":"A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-05-17","conditions":"Hypertension","enrollment":10},{"nctId":"NCT06618079","phase":"PHASE1","title":"Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2024-04-20","conditions":"Hypertension","enrollment":46},{"nctId":"NCT05947448","phase":"","title":"Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study","status":"UNKNOWN","sponsor":"Hasten Biopharmaceutical Co., Ltd.","startDate":"2024-01-22","conditions":"Essential Hypertension","enrollment":1215},{"nctId":"NCT04470817","phase":"","title":"A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2018-08-07","conditions":"Essential Hypertension","enrollment":3438},{"nctId":"NCT04470830","phase":"","title":"A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2019-09-11","conditions":"Essential Hypertension","enrollment":718},{"nctId":"NCT05841654","phase":"PHASE4","title":"Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-06-01","conditions":"Hypertension, Atrial Fibrillation","enrollment":400},{"nctId":"NCT05753696","phase":"NA","title":"Azilsartan in Patients With Diabetic Kidney Disease and Hypertension","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-01","conditions":"Proteinuria, Kidney Dysfunction, Blood Pressure","enrollment":106},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":"Covid19, SARS-CoV Infection","enrollment":341},{"nctId":"NCT03539627","phase":"","title":"Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2018-11-07","conditions":"Arterial Hypertension, Diabetes Mellitus, Stable Chronic Angina","enrollment":184},{"nctId":"NCT05002244","phase":"PHASE1","title":"A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Celltrion","startDate":"2021-07-23","conditions":"Health, Subjective","enrollment":37},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04743063","phase":"","title":"Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-01-14","conditions":"Heart Failure, Systolic, Frailty","enrollment":40000},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT02791438","phase":"PHASE3","title":"A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-18","conditions":"Pediatric Hypertension","enrollment":27},{"nctId":"NCT02541669","phase":"PHASE1","title":"A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-11-20","conditions":"Healthy Volunteer","enrollment":64},{"nctId":"NCT02756819","phase":"","title":"International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-18","conditions":"Hypertension","enrollment":1945},{"nctId":"NCT03434977","phase":"PHASE1","title":"A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-14","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02181816","phase":"","title":"Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06-26","conditions":"Hypertension","enrollment":1090},{"nctId":"NCT02100319","phase":"","title":"Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-03","conditions":"Hypertension","enrollment":387},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT02517866","phase":"PHASE4","title":"Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-07-13","conditions":"Essential Hypertension, Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT02092025","phase":"","title":"Azilsartan Tablets Special Drug Use Surveillance: Long-term Use","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-06-20","conditions":"Hypertension","enrollment":3437},{"nctId":"NCT03042299","phase":"PHASE1","title":"A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-10","conditions":"Japanese Healthy Adult Male Participants","enrollment":14},{"nctId":"NCT02786082","phase":"PHASE1","title":"Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-11-01","conditions":"Hypertension","enrollment":29},{"nctId":"NCT02609490","phase":"PHASE3","title":"Azilsartan in Chinese Patients With Mild and Moderate Hypertension","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-09","conditions":"Hypertension","enrollment":304},{"nctId":"NCT03652792","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-01-22","conditions":"Bioequivalence of Two Azilsartan Formulations","enrollment":60},{"nctId":"NCT01774591","phase":"NA","title":"Effect of Azilsartan on Aldosterone in Postmenopausal Females","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Hypertension","enrollment":21},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT02079805","phase":"PHASE4","title":"A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06","conditions":"Essential Hypertension Complicated by Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT02277691","phase":"PHASE3","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-11-07","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT02203916","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":"Hypertension","enrollment":328},{"nctId":"NCT02401464","phase":"PHASE1","title":"A Bioequivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":"Japanese Healthy Adult Males","enrollment":52},{"nctId":"NCT02400775","phase":"PHASE4","title":"A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2015-03","conditions":"Essential Hypertension With Stable Angina and Dyslipidemia","enrollment":""},{"nctId":"NCT02451150","phase":"PHASE3","title":"A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08","conditions":"Pediatric Hypertension","enrollment":6},{"nctId":"NCT01762501","phase":"NA","title":"Azilsartan Circadian and Sleep Pressure","status":"COMPLETED","sponsor":"Sogo Rinsho Médéfi Co., Ltd.","startDate":"2012-12","conditions":"Hypertension","enrollment":957},{"nctId":"NCT01496430","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":105},{"nctId":"NCT02407210","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-01","conditions":"Essential Hypertension","enrollment":304},{"nctId":"NCT02235519","phase":"PHASE2, PHASE3","title":"Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients","status":"UNKNOWN","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2014-01","conditions":"Hypertension, Obesity, Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT01078376","phase":"PHASE1","title":"A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2010-05","conditions":"Hypertension","enrollment":29},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Essential Hypertension","enrollment":507},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT01985152","phase":"PHASE1","title":"A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Health","enrollment":62},{"nctId":"NCT01609959","phase":"PHASE4","title":"New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering","status":"COMPLETED","sponsor":"Nara Medical University","startDate":"2012-06","conditions":"Hypertension","enrollment":70},{"nctId":"NCT00760214","phase":"PHASE3","title":"Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-01","conditions":"Hypertension","enrollment":885},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT01124656","phase":"PHASE3","title":"Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes Mellitus","enrollment":704},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Hypertension","enrollment":1711},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00591578","phase":"PHASE3","title":"Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-12","conditions":"Hypertension","enrollment":984},{"nctId":"NCT00696384","phase":"PHASE3","title":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":418},{"nctId":"NCT00696241","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":1275},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":566},{"nctId":"NCT00591773","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":"Hypertension","enrollment":551},{"nctId":"NCT00591253","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Hypertension","enrollment":413},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Hypertension","enrollment":1291},{"nctId":"NCT00695955","phase":"PHASE3","title":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":669},{"nctId":"NCT00362115","phase":"PHASE2","title":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Hypertension","enrollment":449},{"nctId":"NCT01289132","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":926},{"nctId":"NCT00376181","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT00759551","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-08","conditions":"Hypertension","enrollment":555}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAK-536","genericName":"TAK-536","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-536 is a small molecule that acts as a Type-1 angiotensin II receptor antagonist. It is being studied in clinical trials for conditions such as hypertension, type 2 diabetes, and diabetes mellitus type 2, often in combination with other medications like amlodipine and pioglitazone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}